Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin with Alpelisib and Fulvestrant in PIK3CA-Mutant mBC
NCT05025735Phase 2Unknown
- Sponsor
- Saint Luke's Health System
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in hyperglycemia, sponsored by Saint Luke's Health System. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT05025735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025735.